Board to Support Execution of Phase 3 Strategy and Long-Term Value Creation
NIJMEGEN, The Netherlands –October 6, 2025 – Khondrion, a late-stage clinical biopharmaceutical company developing therapies for primary mitochondrial diseases, today announced the formation of its Supervisory Board, marking a critical milestone in the company’s evolution toward commercialization. Appointed to the Board are Jan Smeitink, Erik van den Berg, Wanja Allessie, Francois Hoenjet, and Willem van Weperen.
The establishment of the Supervisory Board comes as Khondrion prepares to initiate its registrational Phase 3 clinical trial for its lead candidate sonlicromanol, targeting the m.3243A>G genetic mutation—the most common and a severe and progressive mitochondrial disorder causing classic MELAS, MIDD and other multi-system phenotypes, with no approved treatment options.
Jan Smeitink, Founder and Khondrion’s former CEO, and globally recognized expert in mitochondrial medicine, will serve as Chairman of the Supervisory Board.
“This is an exciting time for Khondrion as we enter a new chapter of clinical and organizational maturity,” said Prof. Smeitink. “With the collective expertise of the new Board, we are well-positioned to support the leadership team in delivering on our mission to bring the first approved therapy to patients with primary mitochondrial disease.”
Erik van den Berg, , brings deep expertise in biotech strategy, corporate development, and organizational growth. He has held executive roles across multiple life sciences ventures and offers valuable insight into strategic scaling and financing.
Wanja Allessie joins the Board as a seasoned transformation executive and member of the SER Topwomen. She brings over two decades of leadership experience in digital innovation, business development, and sustainable growth across diverse sectors.
Francois Hoenjet, partner at Ramphastos and former partner at Loyens & Loeff, is an experienced executive with a strong background in tax, finance, and portfolio management. His expertise will support Khondrion’s capital allocation and growth strategy.
Willem van Weperen, a Termeer Foundation Mentor and biotech industry veteran, brings more than 25 years of experience in commercialization, business development, and executive leadership across multiple healthcare ventures.
The Supervisory Board will provide strategic oversight and governance as Khondrion advances toward late-stage development and future market entry. The Board’s mandate includes ensuring the company’s leadership executes with discipline, transparency, and afocus on long-term value creation.
E-mail: levink@khondrion.com
Tel: +31 24 763 50 00
Website: www.khondrion.com
